https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-08-01 / Breast 2013 Aug;22 Suppl 2:S96-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-08-01 / Breast 2013 Aug;22 Suppl 2:S96-92013-08-01 00:00:002019-02-15 08:50:01Developing an effective breast cancer vaccine: challenges to achieving sterile immunity versus resetting equilibrium
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-07-20 / J Gastrointest Surg 2013 Sep;17(9):1609-17
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-07-20 / J Gastrointest Surg 2013 Sep;17(9):1609-172013-07-20 00:00:002024-08-26 09:28:16Dendritic cell-based immunotherapy targeting synthesized peptides for advanced biliary tract cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-07-13 / Ann. Surg. Oncol. 2013 Oct;20(10):3233-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-07-13 / Ann. Surg. Oncol. 2013 Oct;20(10):3233-92013-07-13 00:00:002019-02-15 08:50:02Response to HER-2 pulsed DC1 vaccines is predicted by both HER-2 and estrogen receptor expression in DCIS
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-07-09 / Clin. Cancer Res. 2013 Sep;19(17):4801-15
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-07-09 / Clin. Cancer Res. 2013 Sep;19(17):4801-152013-07-09 00:00:002019-04-03 09:09:02A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-07-02 / Cancer Immunol. Immunother. 2013 Sep;62(9):1499-509
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-07-02 / Cancer Immunol. Immunother. 2013 Sep;62(9):1499-5092013-07-02 00:00:002019-02-15 08:46:28Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-07-02 / Biology (Basel) 2013 Jul;2(3):936-75
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-07-02 / Biology (Basel) 2013 Jul;2(3):936-752013-07-02 00:00:002021-11-15 16:56:11Oncolytic Newcastle Disease Virus as Cutting Edge between Tumor and Host
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-06-24 / J. Clin. Invest. 2013 Jul;123(7):3135-45
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-06-24 / J. Clin. Invest. 2013 Jul;123(7):3135-452013-06-24 00:00:002019-02-15 08:48:46Melanoma immunotherapy using mature DCs expressing the constitutive proteasome
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-06-21 / Cancer Treat. Rev. 2013 Dec;39(8):891-907
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-06-21 / Cancer Treat. Rev. 2013 Dec;39(8):891-9072013-06-21 00:00:002019-02-15 08:46:27Active immunotherapy using dendritic cells in the treatment of glioblastoma multiforme
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-06-18 / J Transl Med 2013 Jun;11:149
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-06-18 / J Transl Med 2013 Jun;11:1492013-06-18 00:00:002019-02-15 08:52:12A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-06-04 / J Clin Oncol 31, 2013 (suppl; abstr e20042)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-06-04 / J Clin Oncol 31, 2013 (suppl; abstr e20042)2013-06-04 11:44:592019-07-17 11:45:20Biochemical and immunologic markers in patients with metastatic melanoma treated with chemotherapy and dendritic cell vaccine.
